Filtered By:
Education: Study
Vaccination: Vaccines

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 443 results found since Jan 2013.

Guillain-Barre syndrome in Mexico: clinical features and validation of Brighton Collaboration Group criteria
CONCLUSION: GBS is a frequent autoimmune neuropathy that has been associated with preceding infections and with vaccination campaigns. For SARS-CoV-2 vaccination campaign in Mexico, validation of Brighton Criteria is necessary. Although Mexico's GBS epidemiology has been changing throughout recent years, this study provides similar data compared to other countries.PMID:35383873 | DOI:10.33588/rn.7408.2021437
Source: Revista de Neurologia - April 6, 2022 Category: Neurology Authors: J C L ópez-Hernández J A Galnares-Olalde A Guti érrez S A Estrada M Garc ía-Grimshaw E S Vargas-Ca ñas Source Type: research

Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine
Rheumatol Int. 2022 Apr 4. doi: 10.1007/s00296-022-05119-y. Online ahead of print.ABSTRACTMost of the published data relate to classical forms of rheumatic diseases (RD) and information on rare inflammatory disorders such as Behçet's syndrome (BS) and familial Mediterranean fever (FMF) is limited. We studied the frequency of side effects and disease flares after COVID-19 vaccination with either Pfizer/BioNTech or Sinovac/CoronaVac in 256 patients with BS, 247 with FMF, and 601 with RD. Telephone interviews were conducted using a questionnaire survey in a cross-sectional design in patients with BS, FMF, and RD followed by ...
Source: Pain Physician - April 4, 2022 Category: Anesthesiology Authors: Ayse Ozdede Sabriye Guner Guzin Ozcifci Berna Yurttas Zeynep Toker Dincer Zeynep Atli U ğur Uygunoğlu Eser Durmaz Didar U çar Serdal U ğurlu Sabahattin Saip Fehmi Tabak Vedat Hamuryudan Emire Seyahi Source Type: research

Safety of SARS-CoV-2 vaccination in patients with Behcet ’s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine
AbstractMost of the published data relate to classical forms of rheumatic diseases (RD) and information on rare inflammatory disorders such as Beh çet’s syndrome (BS) and familial Mediterranean fever (FMF) is limited. We studied the frequency of side effects and disease flares after COVID-19 vaccination with either Pfizer/BioNTech or Sinovac/CoronaVac in 256 patients with BS, 247 with FMF, and 601 with RD. Telephone interviews were conducte d using a questionnaire survey in a cross-sectional design in patients with BS, FMF, and RD followed by a single university hospital. Study participants were vaccinated either with C...
Source: Rheumatology International - April 4, 2022 Category: Rheumatology Source Type: research

Clinical characteristics of patients with acute ischemic stroke previously vaccinated against COVID-19
The aim of this study was to examine the clinical characteristics of patients with acute ischemic stroke which were previously vaccinated against Coronavirus Disease 2019 (COVID-19) and determine whether the vaccine had impact on outcome.
Source: Journal of Stroke and Cerebrovascular Diseases - April 3, 2022 Category: Neurology Authors: Marija Stamenkovi ć, Ljiljana Radmilo, Mirjana Jovićević, Tamara Rabi-Žikić, Marija Žarkov, Svetlana Ružička-Kaloci, Svetlana Simić, Aleksandar Stamenković, Željko Živanović Source Type: research

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

The hospitalization rate of cerebral venous sinus thrombosis before and during COVID-19 pandemic era: A single-center retrospective cohort study
In this study, we aimed to compare the hospitalization rate of CVST before and during the COVID-19 pandemic (before vaccination program).
Source: Journal of Stroke and Cerebrovascular Diseases - March 24, 2022 Category: Neurology Authors: Maryam Vasaghi Gharamaleki, Maryam Habibagahi, Etrat Hooshmandi, Reza Tabrizi, Shahram Arsang-Jang, Zohreh Barzegar, Nima Fadakar, Vahid Reza Ostovan, Abbas Rahimi-Jaberi, Nahid Ashjazadeh, Peyman Petramfar, Maryam Poursadeghfard, Sadegh Izadi, Masoumeh N Source Type: research

Thrombotic events following Covid-19 vaccines compared to Influenza vaccines
CONCLUSIONS AND RELEVANCE: This study shows a significant increase in thrombotic events in subjects vaccinated with Covid-19 vaccines in comparison to a control group. The clinical implication of these findings should be interpreted with caution, in light of the high effectiveness of vaccination and the inherent risk of thrombosis from Covid-19 infection itself.PMID:35288031 | DOI:10.1016/j.ejim.2022.03.002
Source: European Journal of Internal Medicine - March 15, 2022 Category: Internal Medicine Authors: Marcelo Gabriel Vallone Andre Luis Falc ón Horacio Matias Castro Augusto Ferraris Ramiro Francisco Cantarella Mar ía Inés Staneloni Valeria Ines Aliperti Analia Ferloni Daniela Mezzarobba Fernando Javier V ázquez Mar ía Florencia Grande Ratti Source Type: research

Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
CONCLUSIONS: PPV engenders a long-lasting increase in anti-pneumococcal IgG, and to a lesser extent, IgM titres, as well as a transient increase in anti-OxLDL IgM antibodies. However, there were no detectable changes in surrogate markers of atherosclerosis at the 2-year follow-up. Long-term, prospective follow-up of clinical outcomes is continuing to assess if PPV reduces CVD events.PMID:35290813 | DOI:10.1016/j.atherosclerosis.2022.02.011
Source: Atherosclerosis - March 15, 2022 Category: Cardiology Authors: Shu Ren Philip M Hansbro Wichat Srikusalanukul Jay C Horvat Tegan Hunter Alexandra C Brown Roseanne Peel Jack Faulkner Tiffany-Jane Evans Shu Chuen Li David Newby Alexis Hure Walter P Abhayaratna Sotirios Tsimikas Ayelet Gonen Joseph L Witztum John Attia Source Type: research

Thrombotic events following Covid-19 vaccines compared to Influenza vaccines
CONCLUSIONS AND RELEVANCE: This study shows a significant increase in thrombotic events in subjects vaccinated with Covid-19 vaccines in comparison to a control group. The clinical implication of these findings should be interpreted with caution, in light of the high effectiveness of vaccination and the inherent risk of thrombosis from Covid-19 infection itself.PMID:35288031 | PMC:PMC8904150 | DOI:10.1016/j.ejim.2022.03.002
Source: European Journal of Internal Medicine - March 15, 2022 Category: Internal Medicine Authors: Marcelo Gabriel Vallone Andre Luis Falc ón Horacio Matias Castro Augusto Ferraris Ramiro Francisco Cantarella Mar ía Inés Staneloni Valeria Ines Aliperti Analia Ferloni Daniela Mezzarobba Fernando Javier V ázquez Mar ía Florencia Grande Ratti Source Type: research

Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
Observational studies have demonstrated that the pneumococcal polysaccharide vaccine (PPV) is associated with reduced risk of cardiovascular events. This may be mediated through IgM antibodies to OxLDL, which have previously been associated with cardioprotective effects. The Australian Study for the Prevention through Immunisation of Cardiovascular Events (AUSPICE) is a double-blind, randomised controlled trial (RCT) of PPV in preventing ischaemic events. Participants received PPV or placebo once at baseline and are being followed-up for incident fatal and non-fatal myocardial infarction or stroke over 6 years.
Source: Atherosclerosis - March 5, 2022 Category: Cardiology Authors: Shu Ren, Philip M. Hansbro, Wichat Srikusalanukul, Jay C. Horvat, Tegan Hunter, Alexandra C. Brown, Roseanne Peel, Jack Faulkner, Tiffany-Jane Evans, Shu Chuen Li, David Newby, Alexis Hure, Walter P. Abhayaratna, Sotirios Tsimikas, Ayelet Gonen, Joseph L. Source Type: research

Ischemic stroke shortly after vaccination against SARS-CoV-2: A case-control study
Vaccination against SARS-CoV-2 has been associated with rare occurrences of severe venous thromboses. Very little data exist about arterial ischemic strokes. We have assessed the features of ischemic strokes occurring shortly after vaccination against SARS-CoV-2 in the Cremona area, Italy.
Source: Journal of the Neurological Sciences - February 27, 2022 Category: Neurology Authors: Vinciguerra Luisa, Puglisi Valentina, Giossi Alessia, De Giuli Valeria, Caprioli Francesca, Costanzi Chiara, Pari Elisa, Tripodi Silvia Maria, Trapasso Maria Clauida, Censori Bruno Tags: Clinical short communication Source Type: research

New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Influenza vaccination in patients with heart failure: A protocol for meta-analysis of randomized controlled trials
Discussion: This meta-analysis will evaluate the efficacy and safety of influenza vaccination in heart failure patients, providing evidence to the use of influenza vaccine in these patients. Systematic review registration: INPLASY202210115.
Source: Medicine - February 11, 2022 Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research